Arcadia Biosciences (NASDAQ:RKDA) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research report released on Thursday morning. The brokerage issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.

Arcadia Biosciences Stock Performance

NASDAQ RKDA opened at $4.05 on Thursday. The business’s 50 day moving average price is $3.24 and its 200-day moving average price is $2.96. Arcadia Biosciences has a fifty-two week low of $1.85 and a fifty-two week high of $5.34. The company has a market cap of $5.52 million, a P/E ratio of -0.81 and a beta of 1.27.

Arcadia Biosciences (NASDAQ:RKDA) last posted its quarterly earnings data on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). The firm had revenue of $1.31 million for the quarter, compared to the consensus estimate of $0.95 million. Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. During the same quarter last year, the firm earned ($2.64) EPS. As a group, equities analysts predict that Arcadia Biosciences will post -1.7 EPS for the current year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.